Aquestive OK on diazepam Buccal Film in Pediatric, Update on epinephrine Sublingual Film

 

• Libervant is the first and only FDA approved orally administered rescue product for the treatment of seizure clusters in patients ages 2 to 5
  
• Announces immediate availability of Libervant 5mg, 7.5mg, 10mg, 12.5mg, and 15mg for patients between 2 to 5 years of age
• Company track record now includes 4 FDA approvals since 2018
• Anaphylm program on track; NDA submission expected by the end of 2024
• Hosts conference call for investors on April 29 at 8:00 a.m. ET

Conference Call and Webcast Reminder
The Company will host a conference call at 8:00 a.m. ET on Monday, April 29, 2024.

In order to participate, please register in advance here to obtain a local or toll-free phone number and your personal pin.

A live webcast of the call will be available on Aquestive’s website: FDA Approval for Libervant Investor Call. The webcast will be archived for 30 days.

https://www.globenewswire.com/news-release/2024/04/29/2871087/0/en/Aquestive-Therapeutics-Receives-U-S-FDA-Approval-and-Market-Access-for-Libervant-diazepam-Buccal-Film-in-Pediatric-Patients-Ages-2-to-5-and-Provides-Update-on-Anaphylm-epinephrine-.html